McKesson Shifts Toward High-Margin Specialty Care and Technology Services
McKesson (MCK) is successfully transitioning from a traditional low-margin drug wholesaler into a diversified healthcare services and technology provider. The company's oncology and technology units, while representing only 15% of revenue, contributed nearly 37% of adjusted segment operating profit in the second quarter. This shift is being driven by strategic acquisitions and investments, including the completion of the Precision Medicine Group acquisition and a $1.4 billion investment for a 49% stake in Option Care Health. Management has raised fiscal 2027 adjusted earnings guidance to a range of $45.60 to $46.40 per share, implying growth of 17% to 19%. Further structural changes include the planned spin-off of its medical-surgical business (to be renamed Wellverse) via an IPO in late 2027 and an extended distribution agreement with CVS Health through 2032. These moves aim to provide long-term visibility and higher-margin growth across specialty care, biopharma services, and infusion therapy.
Tickers: $CAH $COR $CVS $MCK $OPCH
Topics: acquisition earnings guidance healthcare services segment performance